Abstract
The life expectancy of advanced stage non-small cell lung cancer patients has increased significantly over the last years due to the introduction of immunotherapy and multiple targeted therapies. One of the most recent important developments is the registration of the KRAS p.G12C targeting agent sotorasib (LUMAKRAS/LUMYKRAS®). The KRAS p.G12C driver mutation is one the most prevalent driver mutations in NSCLC, occurring in 13% of lung adenocarcinomas. Sotorasib causes relevant drug-drug interactions (DDIs), both as a perpetrator (P-gp inhibitor, CYP3A4 inducer) and as a victim (CYP3A4 and P-gp substrate) which may lead to (cancer) treatment inefficacy or serious side effects.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
